title: Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
abstract: Bacterial infections are the most common cause for treatment-related mortality in patients with neutropenia after chemotherapy. Here, we discuss the use of antibacterial prophylaxis against bacteria and Pneumocystis pneumonia (PCP) in neutropenic cancer patients and offer guidance towards the choice of drug. A literature search was performed to screen all articles published between September 2000 and January 2012 on antibiotic prophylaxis in neutropenic cancer patients. The authors assembled original reports and meta-analysis from the literature and drew conclusions, which were discussed and approved in a consensus conference of the Infectious Disease Working Party of the German Society of Hematology and Oncology (AGIHO). Antibacterial prophylaxis has led to a reduction of febrile events and infections. A significant reduction of overall mortality could only be shown in a meta-analysis. Fluoroquinolones are preferred for antibacterial and trimethoprim-sulfamethoxazole for PCP prophylaxis. Due to serious concerns about an increase of resistant pathogens, only patients at high risk of severe infections should be considered for antibiotic prophylaxis. Risk factors of individual patients and local resistance patterns must be taken into account. Risk factors, choice of drug for antibacterial and PCP prophylaxis and concerns regarding the use of prophylactic antibiotics are discussed in the review.
authors: Department of Hematology and Oncology, Georg August University Göttingen, Robert Koch Str. 40, 37075, Göttingen, Germany. silke.neumann@med.uni-goettingen.de
authors: S
authors: S
authors: Neumann
authors: S W
authors: SW
authors: Krause
authors: G
authors: G
authors: Maschmeyer
authors: X
authors: X
authors: Schiel
authors: M
authors: M
authors: von Lilienfeld-Toal
mesh_terms: D019072:Antibiotic Prophylaxis / Q000379:methods; D001424:Bacterial Infections / Q000517:prevention & control*; D005858:Germany; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006405:Hematology / Q000331:legislation & jurisprudence / Q000458:organization & administration; D006801:Humans; D055552:Infectious Disease Medicine / Q000331:legislation & jurisprudence / Q000458:organization & administration; D008495:Medical Oncology / Q000331:legislation & jurisprudence / Q000458:organization & administration; D009369:Neoplasms / Q000188:drug therapy*; D045363:Pneumocystis carinii / Q000502:physiology*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D011322:Primary Prevention / Q000331:legislation & jurisprudence / Q000379:methods* / Q000592:standards; D012955:Societies, Medical / Q000331:legislation & jurisprudence